Cardiovascular risk of BRCA1/2 mutation carriers: A review
- PMID: 27451331
- DOI: 10.1016/j.maturitas.2016.06.012
Cardiovascular risk of BRCA1/2 mutation carriers: A review
Abstract
BRCA1/2 mutation carriers are at high risk of breast and ovarian cancer. The number of studies on non-cancer endpoints in BRCA1/2 mutation carriers is still limited. BRCA1/2 mutation carriers may be at higher cardiovascular risk due to early menopause after risk-reducing salpingo-oophorectomy and/or due to the potential cardiotoxic effects of breast cancer treatment (radiotherapy and chemotherapy). Moreover, BRCA genes have a role as a gatekeeper in cardiac function and structure, which may affect susceptibility to cardiac damage. Our goal is to review current knowledge of cardiovascular risk among BRCA1/2 mutation carriers.
Keywords: BRCA; Cardio-oncology; Cardiotoxicity; Cardiovascular disease; Salpingo-oophorectomy.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
BRCA1/2 mutation carriers are potentially at higher cardiovascular risk.Crit Rev Oncol Hematol. 2014 Aug;91(2):159-71. doi: 10.1016/j.critrevonc.2014.01.008. Epub 2014 Jan 24. Crit Rev Oncol Hematol. 2014. PMID: 24529552 Review.
-
Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.Jpn J Clin Oncol. 2013 May;43(5):515-9. doi: 10.1093/jjco/hyt036. Epub 2013 Mar 13. Jpn J Clin Oncol. 2013. PMID: 23487443
-
Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.JAMA Oncol. 2015 Jun;1(3):306-13. doi: 10.1001/jamaoncol.2015.0658. JAMA Oncol. 2015. PMID: 26181175
-
Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.Eur J Cancer. 2021 May;148:95-102. doi: 10.1016/j.ejca.2021.02.007. Epub 2021 Mar 17. Eur J Cancer. 2021. PMID: 33743487
-
Management updates for women with a BRCA1 or BRCA2 mutation.Mol Diagn Ther. 2007;11(3):133-44. doi: 10.1007/BF03256234. Mol Diagn Ther. 2007. PMID: 17570734 Review.
Cited by
-
A metabolome-wide case-control study of african american breast cancer patients.BMC Cancer. 2023 Feb 23;23(1):183. doi: 10.1186/s12885-023-10656-1. BMC Cancer. 2023. PMID: 36823587 Free PMC article.
-
Cardiovascular disease risk after breast cancer treatment in patients with a BRCA1/2 pathogenic variant.Breast Cancer Res Treat. 2025 Feb;209(3):573-583. doi: 10.1007/s10549-024-07516-2. Epub 2024 Oct 31. Breast Cancer Res Treat. 2025. PMID: 39482556
-
CATCH-KB: Establishing a Pharmacogenomics Variant Repository for Chemotherapy-Induced Cardiotoxicity.AMIA Jt Summits Transl Sci Proc. 2018 May 18;2017:168-177. eCollection 2018. AMIA Jt Summits Transl Sci Proc. 2018. PMID: 29888066 Free PMC article.
-
Beneficial Molecular Adaptations In BRCA-Mutation Carriers By Combined HIT/HIRT Intervention: Results From A Pilot Study.Cancers (Basel). 2020 Jun 10;12(6):1526. doi: 10.3390/cancers12061526. Cancers (Basel). 2020. PMID: 32532068 Free PMC article.
-
Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD).ESMO Open. 2024 Jan;9(1):102196. doi: 10.1016/j.esmoop.2023.102196. Epub 2023 Dec 19. ESMO Open. 2024. PMID: 38118367 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous